Curcumin and its role in chronic diseases

Advances in Experimental Medicine and Biology

Volumn 928, Issue , 2016, Pages 1-25

  Kunwar, A ^a   Priyadarsini, K I ^a  

^a BHABHA ATOMIC RESEARCH CENTRE   (India)

Author keywords

Anti inflammatory; Anticancer; Antioxidant; Curcumin; Polyphenol; Turmeric

Indexed keywords

CURCUMIN; CYTOKINE; DICLOFENAC; GROWTH FACTOR; IMATINIB; PHENYLBUTAZONE; PROTEIN KINASE; TRANSCRIPTION FACTOR;

ALZHEIMER DISEASE; BIOLOGICAL ACTIVITY; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); COLITIS; DIABETES MELLITUS; DISEASE MODEL; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; GENE EXPRESSION; HELICOBACTER INFECTION; HUMAN; INFLAMMATORY BOWEL DISEASE; INTRACELLULAR SIGNALING; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; NONHUMAN; OXIDATIVE STRESS; PANCREAS CANCER; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PSORIASIS; RHEUMATOID ARTHRITIS; TREATMENT DURATION; ANIMAL; DRUG EFFECTS; SIGNAL TRANSDUCTION;

ANIMALS; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; CURCUMIN; HUMANS; SIGNAL TRANSDUCTION;

EID: 84988971938     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-3-319-41334-1_1     Document Type: Chapter

References (124)

1. Agarwal R, Goel SK, Behari JR (2010) Detoxification and antioxidant effects of curcumin in rats experimentally exposed to mercury. J Appl Toxicol 30:457–468
2. Aggarwal BB (2010) Targeting inflammation induced obesity and metabolic diseases by curcumin and other nutraceuticals. Annu Rev Nutr 30:173–199
3. Aggarwal BB, Sung B (2009) Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci 30:85–94
4. Aggarwal BB, Kumar A, Bharti AC (2003) Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 23:363–398
5. Aggarwal BB, Shishodia S, Takada Y et al (2005) Curcumin suppresses the paclitaxel induced nuclear factor-κB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res 11:7490–7498
6. Aggarwal BB, Sundaram C, Malini N et al (2007) Curcumin: the Indian solid gold. Adv Exp Med Biol 595:243–305
7. Aggarwal BB, Gupta SC, Sung B (2013) Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers. Br J Pharmacol 169(8):1672–1692
8. Alrawaiq NS, Abdullah A (2014) A review of antioxidant polyphenol curcumin and its role in detoxification. Int J PharmTech Res 6:280–289
9. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB (2007) Bioavaialbility of curcumin: problems and promises. Mol Pharm 4:807–818
10. Arbiser JL, Klauber N, Rohan R, van LR, Huang MT, Fisher C, Flynn E, Byers HR (1998) Curcumin is an in vivo inhibitor of angiogenesis. Mol Med 4:376–383
11. Asai A, Miyazawa T (2000) Occurrence of orally administered curcuminoid as glucuronide and glucuronide/sulfate conjugates in rat plasma. Life Sci 67:2785–2793
12. Asti M, Ferrari E, Groci S et al (2014) 68Ga-labelled curcuminoids complexes: characterisation of potential radiotracers for imaging of Alzheimer’s disease. Inorg Chem 53:4922–4933
13. Awasthi A, Pandya U, Singhal SS et al (2000) Curcumin–glutathione interactions and the role of human glutathione S-transferase PI-1. Chem Biol Interact 128:19–38
14. Bae MK, Kim SH, Jeong JW et al (2006) Curcumin inhibits hypoxia-induced angiogenesis via down-regulation of HIF-1. Oncol Rep 15:1557–1562
15. Barik A, Mishra B, Shen L et al (2005) Evaluation of new copper–curcumin complex as superoxide dismutase mimic and its free radical reactions. Free Radic Biol Med 39:811–822
16. Baum L, Lam CW, Cheung SK et al (2008) Six month randomized placebo controlled double blind pilot clinical trial of curcumin in patients of Alzheimer disease. J Clin Psychopharmacol 28:110–113
17. Bayet-Robert M, Kwaitkowski F, Leheurteur M et al (2010) Phase I dose escalation trial of docataxel plus curcumin in patients with advanced metastatic breast cancer. Cancer Biol Ther 9:8–14
18. Beloqui A, Coco R, Memvanga PB et al (2014) pH sensitive nanoparticles for colonic delivery in inflammatory bowel disease. Int J Pharm 473:203–212
19. Bharti AC, Donato N, Aggarwal BB (2003) Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 171:3863–3871
20. Bierhaus A, Zhang Y, Quehenberger P et al (1997) The dietary pigment curcumin reduces endothelial tissue factor gene expression by inhibiting binding of AP-1 to the DNA and activation of NF-κB. Thromb Haemost 77:772–782
21. Chan MM, Huang HI, Fenton MR, Fong D (1998) In vivo inhibition of nitric oxide synthase gene expression by curcumin: a cancer preventive natural product with anti-inflammatory properties. Biochem Pharmacol 55:1955–1962
22. Chattopadhyay I, Biswas K, Bandyopadhyay U et al (2004) Turmeric and curcumin: biological actions and medicinal applications. Curr Sci 87:44–53
23. Chattopadhyay I, Bandyopadhyay U, Biswas K et al (2006) Indomethacin inactivates gastric peroxidase to induce reactive-oxygen-mediated gastric mucosal injury and curcumin protects it by preventing peroxidase inactivation and scavenging reactive oxygen. Free Radic Biol Med 40:1397–1408
24. Chen A, Xu J (2005) Activation of PPARγ by curcumin inhibits Moser cell growth and mediates suppression of gene expression of cyclin D1 and EGFR. Am J Physiol Gastrointest Liver Physiol 288:G447–G456
25. Chen WH, Chen Y, Cui GH et al (2004) Effect of curcumin on STAT5 signaling pathway in primary CML cells. Zhonghua Xue Ye Xue Za Zhi 12:572–576
26. Chen A, Xu J, Johnson AC (2006) Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1. Oncogene 25:278–287
27. Choudhuri T, Pal S, Das T, Sa G (2005) Curcumin selectively induces apoptosis in deregulated cyclin D1-expressed cells at G2 phase of cell cycle in a p53-dependent manner. J Biol Chem 280:20059–20068
28. Chua CC, Hamdy RC, Chua BH (2000) Mechanism of transforming growth factor-β1-induced expression of vascular endothelial growth factor in murine osteoblastic MC3T3-E1 cells. Biochim Biophys Acta 1497:69–76
29. Collett GP, Campbell FC (2004) Curcumin induces c-Jun N-terminal kinase-dependent apoptosis in HCT116 human colon cancer cells. Carcinogenesis 25:2183–2189
30. Conney AH (2003) Enzyme induction and dietary chemicals as approaches to cancer chemoprevention: the Seventh DeWitt S. Goodman lecture. Cancer Res 63:7005–7031
31. Dhillon N, Aggarwal BB, Newman RA et al (2008) Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14:4491–4499
32. Kim DS, Kim JY, Han Y (2012) Curcuminoids in neurodegenerative diseases. CNS drug Discov 7:184–204
33. Durgaprasad S, Pai CG, Kumar V et al (2005) A pilot study of the antioxidant effect of curcumin in tropical pancreatic. Ind J Med Res 122:315–318
34. Epelbaum R, Schaffer M, Vizel B et al (2010) Curcumin and gemcitabine in patients with advanced pancreatic cancer. Nutr Cancer 62:1137–1141
35. Esatbeyoglu T, Huebbe P, Insa MA et al (2012) Curcumin—from molecule to biological function. Angew Chem Int Ed 51:5308–5332
36. Fang J, Jun L, Holmegren A (2005) Thioredoxin reductase is irreversibly modified by curcumin: a novel molecular mechanism for its anticancer activity. J Biol Chem 280:25284–25290
37. Garcea G, Jones DJ, Singh R et al (2004) Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer 90:1011–1015
38. Garcea G, Berry DP, Jones DJ et al (2005) Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacokinetic consequences. Cancer Epidemiol Biomarkers Prev 14:120–125
39. George D (2003) Targeting PDGF receptors in cancer–rationales and proof of concept clinical trials. Adv Exp Med Biol 532:141–151
40. Ghalaut VS, Sangwan L, Dahiya K et al (2012) Effect of imatinib therapy with and without turmeric powder on nitric oxide levels in chronic myeloid leukemia. J Oncol Pharm Pract 18:186–190
41. Golombick T, Diamond TH, Badmaev V et al (2009) The potential role of curcumin in patients with monoclonal gammopathy of undefined significance—its effect on paraproteinemia type I collagen bone turnover marker. Clin Cancer Res 15:5917–5922
42. Gupta S, Prasad S, Ji HK et al (2011) Multitargeting by curcumin as revealed by molecular interaction studies. Nat Prod Rep 28:1937–1955
43. Gupta SC, Patchva S, Aggarwal BB (2013) Therapeutic potential of curcumin: lessons learned from clinical trials. AAPS J 15:195–218
44. Hamaguchi T, Ono K, Yamada M (2010) Review: curcumin and Alzheimer’s disease. CNS Neurosci Ther 16:285–297
45. Han SS, Chung ST, Robertson DA, Ranjan D, Bondada S (1999) Curcumin causes the growth arrest and apoptosis of B cell lymphoma by downregulation of egr-1, c-myc, bcl-XL, NF-κB, and p53. Clin Immunol 93:152–161
46. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144: 646–674
47. Hanai H, Sugimoto K (2009) Curcumin has prospects for the treatment of inflammatory bowel disease. Curr Pharma Des 15:2087–2094
48. Hanai H, Iida T, Takeuchi K et al (2006) Curcumin maintenance therapy for ulcerative colitis randomized multicenter, double-blind placebo controlled trial. Clin Gastroentero Heatol 4:1502–1506
49. Hasima N, Aggarwal BB (2012) Cancer-linked targets modulated by curcumin. Int J Biochem Mol Biol 3:328–351
50. He ZY, Shi CB, Wen H et al (2011) Upregulation of p53 expression in cancer patients with colorectal cancer by administration of curcumin. Cancer Investig 29:208–213
51. He ZY, Yue Y, Zheng X, Zhang K, Chen S, Du Z et al (2015) Curcumin, inflammation, and chronic diseases: how are they linked? Molecules 20(5):9183–9213
52. Hong RL, Spohn WH, Hung MC (1999) Curcumin inhibits tyrosine kinase activity of p185neu and also depletes p185neu. Clin Cancer Res 5:1884–1891
53. Hoque M, Gong P, Killeen E, Green CJ, Foresti R, Alam J, Motterlini R (2003) Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element. Biochem J 371:887–895
54. Hussain AR, Al-Rasheed M, Manogaran PS et al (2006) Curcumin induces apoptosis via inhibition of PI3′-kinase/AKT pathway in acute T cell leukemias. Apoptosis 11:245–254
55. Ide H, Tokiwa S, Sakamaki K et al (2010) Combined inhibitory effects of soy isoflavons and curcumin on the production of prostate specific antigen. Prostate 70:1127–1133
56. Ireson RC, Jones DJL, Orr S et al (2002) Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemol Biomarkers Prev 11:105–111
57. Jaiswal AS, Marlow BP, Gupta N et al (2002) Beta-catenin-mediated transactivation and cell–cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells. Oncogene 21:8414–8427
58. Jiang T, Zhi X, Zhang Y, Pan L, Zhou P (2012) Inhibitory effect of curcumin on the Al(III)-induced A β(42) aggregation and neurotoxicity in vitro. Biochim Biophys Acta Mol Basis Dis 1822:1207–1215
59. Jun S, Yi Z, Jinhong H (2013) Curcumin inhibits imiquimod induced psoriasis like inflammation by inhibiting IL-1β and IL-6 production in mice. PLoS One 8:e67078
60. Kanai M, Yoshimura K, Asada M et al (2011) A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother Pharmacol 68:157–164
61. Kang ES, Woo IS, Kim HJ et al (2007) Up-regulation of aldose reductase expression mediated by phosphatidylinositol 3-kinase/Akt and Nrf2 is involved in the protective effect of curcumin against oxidative damage. Free Radic Biol Med 43:535–545
62. Kang ES, Kim GH, Kim HJ et al (2008) Nrf2 regulates curcumin-induced aldose reductase expression indirectly via nuclear factor-κB. Pharmacol Res 58:15–21
63. Kawamori T, Lubet R, Steele VE et al (1999) Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. Cancer Res 59:597–601
64. Khan N, Afaq F, Mukhtar H (2008) Cancer chemoprevention through dietary antioxidants: progress and promise. Antioxid Redox Signal 10:475–510
65. Kunwar A, Barik A, Pandey R, Priyadarsini KI (2006) Transport of liposomal and albumin loaded curcumin to living cells: an absorption and fluorescence spectroscopic study. Biochim Biophys Acta (General) 1760:1513–1520
66. Kurd SK, Smith N, Van Voorhees A et al (2008) Oral curcumin in the treatment of moderate to severe psoriasis vulgaris, a prospective clinical trial. J Am Acd Dermatol 58:625–631
67. Kuttan R, Sreedharan PC, Joseph CD (1987) Turmeric and curcumin as topical agents in cancer therapy. Tumori 73:29–31
68. Lampe V, Milobedzka J (1913) Studien uber curucmin. Ber Dtsch Chem Ges 46:2235–2240
69. Lee WH, Loo CY, Bebawy M, Luk F, Mason RS, Rohanizadeh R (2013) Curcumin and its derivatives: their application in neuropharmacology and neuroscience in the 21st century. Curr Neuropharmacol 11(4):338–378
70. Li N, Chen X, Han C, Chen J (2002) Chemopreventive effect of tea and curcumin on DMBA-induced oral carcinogenesis in hamsters. Wei Sheng Yan Jiu 31:354–357
71. Li L, Braiteh FS, Kurzrock R (2005) Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 104:1322–1331
72. Liu JY, Lin SJ, Lin JK (1993) Inhibitory effects of curcumin on protein kinase C activity induced by 12-O-tetradecanoyl-phorbol-13-acetate in NIH 3T3 cells. Carcinogenesis 14:857–861
73. Meng BI, Li J, Cao H (2013) Antioixidant and anti-inflammatory activities of curcumin on diabetes mellitus and its complications. Curr Pharm Des 19:2101–2103
74. Milobedzka J, Kostanecki S, Lampe V (1910) Zur Kenntnis des Curcumins. Berichte der Deutschen Chemischen Gessellschaft 43:2163–2170
75. Monroy A, Lithgow GJ, Alavez S (2013) Curcumin and neurodegenerative diseases. BioFactors 39:122–132
76. Moon DO, Kim MO, Choi YH et al (2010) Curcumin attenuates inflammatory response in IL-1 bets induced human synovial fibroblasts and collagen induced arthritis in mouse model. Int Immunopharmacol 10:605–610
77. Mori Y, Tatematsu K, Koide A et al (2006) Modification by curcumin of mutagenic activation of carcinogenic N-nitrosamines by extrahepatic cytochromes P-450 2B1 and 2E1 in rats. Cancer Sci 97:896–904
78. Noorafshan A, Ashkani-Esfahani S (2013) A review of therapeutic effects of curcumin. Curr Pharm Des 19:2032–2046
79. Oppenheimer A (1937) Turmeric in biliary diseases. Lancet 229:619–621
80. Pabon HJ (1964) Synthesis of curcumin and related compounds. Rev Trav Chim 83:379–386
81. Pallikkavil R, Ummathur MS, Sreedharan S, Krishnankutty K (2013) Synthesis, characterization and antimicrobial studies of Cd(II), Hg(II), Pb(II), Sn(II) and Ca(II) complexes of curcumin. Main Group Met Chem 36:123–127
82. Park SD, Jung JH, Lee HW et al (2005) Zedoariae rhizome and curcumin inhibits platelet-derived growth factor-induced proliferation of human hepatic myofibroblasts. Int Immunopharmacol 5:555–569
83. Park W, Ruhul Amin ARM, Chen ZG, Shin DM (2013) New perspectives of curcumin in cancer prevention. Cancer Prev Res 6:387–400
84. Párkányi C, Stem-Beren MR, Martı́nez OR Aaron JJ, MacNair MB, Arrieta AF (2004) Solvatochromic correlations and ground-and excited-state dipole moments of curcuminoid dyes. Spectrochim Acta A 60:1805–1810
85. Perkins S, Verschoyle RD, Hill K et al (2002) Chemopreventive efficacy and pharmacokinetics of curcumin in mouse, a model of familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev 11:535–540
86. Prasad S, Tyagi AK, Aggarwal BB (2014) Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice. Cancer Res Treat 46:2–18
87. Priyadarsini KI (1997) Free radical reactions of curcumin in model membranes. Free Radic Biol Med 23:838–884
88. Priyadarsini KI (2009) Photophysics, photochemistry and photobiology of curcumin: studies from organic solutions, bio-mimetics and living cells. J Photochem Photobiol C Chem Rev 10:81–96
89. Priyadarsini KI (2013) Chemical and structural features influencing the biological activity of curcumin. Curr Pharm Des 19:2093–2100
90. Priyadarsini KI (2014) The chemistry of curcumin: from extraction to therapeutic agent. Molecules 19:20091–20112
91. Ramadan G, El-Menshawy O (2013) Protective effects of ginger–turmeric rhizomes mixture on joint inflammation, atherogenesis, kidney disfunction and other complications in a rat model of human rheumatoid arthritis. Int J Rheum Dis 16:219–229
92. Ranjan D, Chen C, Johnston H, Jeon H, Nagabhushan M (2004) Curcumin inhibits mitogen stimulated lymphocyte proliferation, NFkappaB activation, and IL-2 signaling. J Surg Res 121:171–177
93. Reddy S, Rishi AK, Xu H et al (2006) Mechanisms of curcumin-and EGF-receptor related protein (ERRP)-dependent growth inhibition of colon cancer cells. Nutr Cancer 55:185–194
94. Rushworth SA, Ogborne RM, Charalambos CA, O’Connell MA (2006) Role of protein kinase C δ in curcumin-induced antioxidant response element-mediated gene expression in human monocytes. Biochem Biophys Res Commun 341(4):1007–1016
95. Sagnou M, Benaki D, Triantis C et al (2011) Curcumin as the OO bidentate ligand in “2 + 1” complexes with the [M(CO)(3)](+) (M = Re, 99mTc) tricarbonyl core for radiodiagnostic applications. Inorg Chem 50:1295–1303
96. Schraufstatter E, Bernt H (1949) Antibacterial action of curcumin and related compounds. Nature 164:456–457
97. Shanmugam MK, Rane G, Kanchi MM et al (2015) The multifaceted role of curcumin in cancer prevention and treatment. Molecules 20:2728–2769
98. Sharma OP (1976) Antioxidant activity of curcumin and related compounds. Biochem Pharmacol 25:1811–1812
99. Sharma KK, Chandra S, Basu DK (1987) Synthesis and antiarthritic study of a new orally active diferuloyl methane (curcumin) gold complex. Inorg Chim Acta 135:47–48
100. Sharma RA, Euden SA, Platton SL et al (2004) Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 10:6847–6854
101. Shehzad A, Rehman G, Lee YS (2013) Curcumin in inflammatory diseases. BioFactors 39:69–77
102. Shen L, Ji HF (2012) The pharmacology of curcumin: is it the degradation products? Trends Mol Med 18:138–143
103. Shen G, Xu C, Hu R et al (2006) Modulation of nuclear factor E2-related factor 2—mediated gene expression in mice liver and small intestine by cancer chemopreventive agent curcumin. Mol Cancer Ther 5:39–51
104. Shishodia S, Amin HM, Lai R, Aggarwal BB (2005) Curcumin (diferuloylmethane) inhibits constitutive NF-κB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem Pharmacol 70:700–713
105. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PSSR (1998) Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 64:353–356
106. Shrimal RC, Dhawan BN (1973) Pharmacology of diferuloyl methane (curcumin), a non-steroidal anti-inflammatory agent. J Pharm Pharmacol 25:447–452
107. Singh S (2007) From exotic spice to modern drug? Cell 130:765–768
108. Singh S, Aggarwal B (1995) Activation of transcription factor NF-κB is suppressed by curcumin (Diferuloylmethane). J Biol Chem 270:24995–25000
109. Srinivasan M (1972) Effect of curcumin on blood sugar as seen in a diabetic subject. Ind J Med Sci 26:269–270
110. Strimpakos AS, Sharma RA (2008) Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal 10:511–545
111. Taylor RA, Leonard MC (2011) Curcumin for inflammatory bowel disease, a review of human studies. Alt Med Rev 16:152–156
112. Tsvetkov P, Asher G, Reiss V, Shaul Y, Sachs L, Lotem J (2005) Inhibition of NAD(P)H: quinone oxidoreductase 1 activity and induction of p53 degradation by the natural phenolic compound curcumin. Proc Natl Acad Sci USA 102:5535–5540
113. Vadhan-Raj S, Weber D, Wang M et al (2007) Curcumin downregulates NF-κB and related genes in patients with multiple myeloma: results of phase 1/2 study. Blood 110:357a
114. Vajragupta O, Boonchoong P, Watanabe H et al (2003) Manganese complexes of curcumin and its derivatives: evaluation for the radical scavenging ability and neuroprotective activity. Free Radic Biol Med 35:1632–1644
115. Vogel HA, Pelletier J (1815) Curcumin-biological and medicinal properties. J Pharma 2:50
116. Wang YJ, Pan MH, Cheng AL et al (1997) Stability of curcumin in buffer solution and characterization of its degradation products. J Pharma Biomed Anal 15:1867–1876
117. Wanninger S, Lorenz V, Subhan A, Edelmann FT (2015) Metal complexes of curcumin— synthetic strategies, structures and medicinal applications. Chem Soc Rev 44:4986–5002
118. Xia Y, Jin L, Zhang B et al (2007) The potentiation of curcumin on insulin-like growth factor-1 action in MCF-7 human breast carcinoma cells. Life Sci 80:2161–2169
119. Xu J, Fu Y, Chen A (2003) Activation of peroxisome proliferator-activated receptor gamma contributes to the inhibitory effects of curcumin on rat hepatic stellate cell growth. Am J Physiol Gastrointest Liver Physiol 285:G20–G30
120. Yallapu MM, Ebeling MC, Khan S et al (2013) Novel curcumin-loaded magnetic nanoparticles for pancreatic cancer treatment. Mol Cancer Ther 12:1471–1480
121. Yang C, Su X, Liu A et al (2013) Advances in clinical study of curcumin. Curr Pharm Des 19:1966–1973
122. Yu S, Shen G, Kong TA (2006) Curcumin inhibits mTOR signaling by inhibiting protein kinase B/Akt and activating AMP-activated protein kinase (AMPK) in prostate cancer cell line PC-3. Proc Am Assoc Cancer Res 47:538
123. Zhang X, Yin WK, Shi XD, Li Y (2011) Curcumin activates Wnt/β-catenin signaling pathway through inhibiting the activity of GSK-3β in APPswe transfected SY5Y cells. Eur J Pharm Sci 42:540–546
124. Zhang D-W, Fu M, Gao S-H, Liu J-L (2013) Curcumin and diabetes: a systematic review. Evid Complement Altern Med 16:1–22